Trial Profile
EVESOR: a Phase 1 Trial of Everolimus and Sorafenib to Assess the Impact of Doses and Administration Sequences on Pharmacokinetic and Pharmacodynamic Effects of the Combination
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms EVESOR
- Sponsors Hospices Civils de Lyon
- 07 Jun 2016 Interim results (n=26) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 03 Sep 2013 New trial record